Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIGHT trial of bermekimab in systemic sclerosis
2018-004655-20Phase 2Completed
- Sponsor
- Hellenic Institute for the Study of Sepsis
- Start
- Jan 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in systemic sclerosis (SSc) comparing Bermekimab with Placebo (2 arms). Primary endpoint: Score of inhibition of SSc progression. Started Jan 2019; status: completed.
02
Drugs
bermekimab
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on 2018-004655-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004655-20.